Generic Name and Formulations:
Patiromer 8.4g, 16.8g, 25.2g; per pkt; pwd for oral susp.
Indications for VELTASSA:
Limitations Of use:
Not for emergency treatment for life-threatening hyperkalemia due to its delayed onset of action.
Give at least 3hrs before or 3hrs after other oral medications. Take without regard to food; mix with water. Initially 8.4g once daily. Adjust dose in 8.4g increments as needed at ≥1-week intervals to obtain desired serum potassium target range; max 25.2g/day.
Binding to other oral medications.
Avoid in severe constipation, bowel obstruction or impaction, abnormal post-op bowel motility disorders. Monitor serum potassium, magnesium. Consider magnesium supplementation if low serum levels develop.
May reduce absorption and efficacy of other oral medications; separate dosing by at least 3hrs.
Constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, flatulence.
Single-use packets (8.4g)—4, 30; (16.8g, 25.2g)—30
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd